Endpoints News

Mixed data for Astellas' stem cell eye therapy		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

8 May, 2026

Where regulators and industry align on what's next.

sponsored by DIA

presented by

Biocon’s Bold Integration: Unifying Biosimilars and Generics to Redefine Global Affordable Access

SPOTLIGHT

Post-Hoc Live: The GLP-1 pill battle, biotech M&A, patent cliffs and more

news

Odyssey raises more than $300M as biotech goes public in IPO

Astellas touts data from early test of stem cell-derived eye therapy

Peer Review

Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech

May 12

10:30 am ET

Rules of engagement: How G3BP2 paves the way to rationalize novel degrons

in case you missed it

Amazon adds Ozempic pill to same-day prescription drug kiosks

Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure

EnGene's shares crash on updated pivotal bladder cancer data

Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst

Blackstone puts $250M into Anagram to tackle cystic fibrosis complication

News Briefing

Entrada stock falls on Duchenne data; Wegovy expands access

Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

Former OpenAI Researcher To Raise $500 Million For AI Science Startup

A senior FDA official will be joining us at Endpoints and the FT's US Pharma and Biotech Summit next Thursday. US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. You won't want to miss it! Join us in New York or virtually here.